On November 28, Beigene announced that the company's independently developed anti-PD-1 antibody, Baizean (reletuzumab injection), and BTK inhibitor Baizean (zebulinib capsules) have added three new indications and one indication respectively were included in the new national medical insurance drug list; the cooperatively introduced product Baituowei (Ivosidenib injection) added one indication to the national medical insurance drug list, and Calos (Carfilzomib injection) successfully renewed.
百济神州：商业化产品多项新增适应症被纳入2024国家医保药品目录
Beigene: Several new indications for commercial products have been included in the 2024 National Health Insurance Pharmaceutical List.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated